trending Market Intelligence /marketintelligence/en/news-insights/trending/oQF2IyOBjSg57NVigcDNRg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Cardax plans $15M offering to fund drug development

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Cardax plans $15M offering to fund drug development

Cardax Inc. is planning to sell up to $15 million of its common stock and warrants in a follow-on public offering.

The Honolulu-based biopharmaceutical company plans to use the net proceeds to develop its drug candidate CDX-101 through investigational new drug and phase 1 clinical testing.

Cardax is developing the therapy for cardiovascular inflammation and dyslipidemia — or an abnormal level of lipids in the blood — with an target initial indication of severe hypertriglyceridemia, or high levels of fatty molecules in the blood.

Proceeds will also be used to complete a trial involving its dietary supplement ZanthoSyn.

Meanwhile, the company said it is in the process of applying to list its common stock on the Nasdaq Capital Market.

Maxim Group LLC is acting as the sole book-running manager for the proposed offering on a "firm commitment" basis.